Literature DB >> 25299637

Sugammadex: A Scientific Review Including Safety and Efficacy, Update on Regulatory Issues, and Clinical Use in Europe.

Jonathan S Jahr1, John E Miller, Jessica Hiruma, Katie Emaus, Michelle You, Claude Meistelman.   

Abstract

Muscle relaxants are used in the perioperative period to aid in endotracheal intubation, facilitate surgical exposure, and in the critical care setting for prolonged relaxation. Until now, the only mechanism to reverse their effect is acetylcholinesterase inhibitors that result in excess parasympathetic activity and require the second drug to prevent this side effect. Additionally, the onset and degree of neuromuscular antagonism are often unpredictable and unreliable. Sugammadex is the first of the cyclodextrins to be used as a therapeutic agent. It quickly, effectively, and safely reverses steroidal neuromuscular blockers by encapsulating the muscle relaxant and rendering it inactive. Sugammadex may be considered the ideal reversal agent and the first drug in its class, which will likely change the practice of anesthesia and clinical neuromuscular pharmacology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25299637     DOI: 10.1097/MJT.0000000000000092

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  4 in total

1.  Laparoscopic partial nephrectomy in a patient on simvastatin : Delayed recovery from neuromuscular blockade.

Authors:  E E Abd El-Hakeem; A M Kaki; S A Almazlom; A J Alsayyad
Journal:  Anaesthesist       Date:  2017-03-06       Impact factor: 1.041

2.  Airway Management via Laryngeal Mask in Laryngotracheal Resection.

Authors:  Patrick Zardo; Tom Kreft; Thomas Hachenberg
Journal:  Thorac Cardiovasc Surg Rep       Date:  2015-11-24

3.  Cyclodextrins: Assessing the Impact of Cavity Size, Occupancy, and Substitutions on Cytotoxicity and Cholesterol Homeostasis.

Authors:  Lajos Szente; Ashutosh Singhal; Andras Domokos; Byeongwoon Song
Journal:  Molecules       Date:  2018-05-20       Impact factor: 4.411

4.  Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery.

Authors:  Kate Mostoller; Rebecca Wrishko; Lata Maganti; W Joseph Herring; Mariëlle van Zutphen-van Geffen
Journal:  Clin Transl Sci       Date:  2020-12-16       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.